[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR084122A1 - COMBINACIONES FARMACEUTICAS, DE UN AGONISTA DE RECEPTOR b-3 ADRENERGICO Y UN ANTAGONISTA DE RECEPTOR MUSCARINICO - Google Patents

COMBINACIONES FARMACEUTICAS, DE UN AGONISTA DE RECEPTOR b-3 ADRENERGICO Y UN ANTAGONISTA DE RECEPTOR MUSCARINICO

Info

Publication number
AR084122A1
AR084122A1 ARP110102798A ARP110102798A AR084122A1 AR 084122 A1 AR084122 A1 AR 084122A1 AR P110102798 A ARP110102798 A AR P110102798A AR P110102798 A ARP110102798 A AR P110102798A AR 084122 A1 AR084122 A1 AR 084122A1
Authority
AR
Argentina
Prior art keywords
receiver
pharmaceutical combinations
muscarinic
adrenergic
agonist
Prior art date
Application number
ARP110102798A
Other languages
English (en)
Inventor
Stewart Mcallum
Eliot Ohlstein
Stephen Caltabiano
Original Assignee
Altherx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altherx Inc filed Critical Altherx Inc
Publication of AR084122A1 publication Critical patent/AR084122A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinaciones farmacéuticas que comprenden un agonista de receptor b-3 adrenérgico y un antagonista de receptor muscarínico y métodos para su uso. Las combinaciones reveladas incluyen solbegron y oxibutirina. Métodos de uso de las combinaciones farmacéuticas para el tratamiento de uno o más síntomas asociados a la vejiga sobreactiva, por ejemplo, frecuencia de urgencia, nocturna e incontinencia urinaria.Reivindicación 12: El uso de acuerdo con cualquiera de las reivindicaciones 10 - 11, caracterizado porque el componente (i) además comprende el compuesto de la fórmula (1).
ARP110102798A 2010-08-03 2011-08-03 COMBINACIONES FARMACEUTICAS, DE UN AGONISTA DE RECEPTOR b-3 ADRENERGICO Y UN ANTAGONISTA DE RECEPTOR MUSCARINICO AR084122A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37017110P 2010-08-03 2010-08-03

Publications (1)

Publication Number Publication Date
AR084122A1 true AR084122A1 (es) 2013-04-24

Family

ID=44511540

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102798A AR084122A1 (es) 2010-08-03 2011-08-03 COMBINACIONES FARMACEUTICAS, DE UN AGONISTA DE RECEPTOR b-3 ADRENERGICO Y UN ANTAGONISTA DE RECEPTOR MUSCARINICO

Country Status (19)

Country Link
US (1) US8642661B2 (es)
EP (1) EP2600859A1 (es)
JP (2) JP2013535486A (es)
KR (2) KR20130135239A (es)
CN (1) CN103269692B (es)
AP (1) AP2013006742A0 (es)
AR (1) AR084122A1 (es)
AU (1) AU2011285928B9 (es)
BR (1) BR112013002511A2 (es)
CA (1) CA2807135C (es)
CL (1) CL2013000342A1 (es)
CO (1) CO6680685A2 (es)
EA (1) EA030145B1 (es)
MX (1) MX353105B (es)
NZ (1) NZ607485A (es)
PE (1) PE20131341A1 (es)
SG (2) SG187689A1 (es)
TW (1) TW201208667A (es)
WO (1) WO2012018773A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2016004056A1 (en) * 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
CN104602693A (zh) * 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
TR201908031T4 (tr) * 2014-08-26 2019-06-21 Astellas Pharma Inc İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu.
JP2017537165A (ja) * 2014-12-03 2017-12-14 ヴェリセプト セラピューティクス、インク． 下部尿路系症状を対象とした徐放性ソラベグロンの組成物及び使用方法
EP3362140A1 (en) * 2015-10-15 2018-08-22 Duke University State-dependent peripheral neuromodulation to treat bladder dysfunction
DK3365321T3 (da) * 2015-10-23 2024-01-15 B3Ar Therapeutics Inc Solabegron-zwitterion og anvendelser deraf
EP3463312A4 (en) * 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. DOSING SCHEMES FOR BETA-3-ADRENOCEPTORAGONISTS AND ANTIMUS CARINICAS FOR THE TREATMENT AND PREVENTION OF SYMPTOMS OF THE LOWER URINARY PATHWAYS AND OVERACTIVE BLADDER
US20170348263A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
CN117695286A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
WO2024086240A1 (en) * 2022-10-18 2024-04-25 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (es) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
AU715216B2 (en) 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
CA2398199A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
MXPA06004625A (es) 2003-11-03 2006-06-27 Boehringer Ingelheim Int Composicion famaceutica que contiene un agonista de un adrenoceptor beta-3 y un antagonista alfa y/o un inhibidor de la 5-alfa-reductasa.
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
EP1804778A1 (de) * 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
SI1871347T1 (sl) 2005-04-19 2016-11-30 Novartis Ag Farmacevtski sestavek
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US20100113469A1 (en) * 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
WO2009057685A1 (ja) 2007-11-02 2009-05-07 Astellas Pharma Inc. 過活動膀胱治療用医薬組成物
JP2011516482A (ja) 2008-04-04 2011-05-26 メルク・シャープ・エンド・ドーム・コーポレイション β３アドレナリン作動性受容体アゴニストとしてのヒドロキシメチルピロリジン
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
WO2010118291A2 (en) * 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US8618144B2 (en) 2009-05-08 2013-12-31 Merck Sharp & Dohme Corp Pyrrolidine-derived beta 3 adrenergic receptor agonists
US8604038B2 (en) 2009-08-27 2013-12-10 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
WO2011025690A1 (en) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
EP2483525B1 (en) 2009-10-02 2020-06-17 Delta T, LLC Air fence for fan blade
CN102638987A (zh) * 2009-10-07 2012-08-15 默沙东公司 使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists

Also Published As

Publication number Publication date
WO2012018773A1 (en) 2012-02-09
EP2600859A1 (en) 2013-06-12
EA201390066A1 (ru) 2013-07-30
CL2013000342A1 (es) 2013-06-28
AU2011285928B2 (en) 2016-06-16
CA2807135C (en) 2019-05-14
US8642661B2 (en) 2014-02-04
PE20131341A1 (es) 2013-12-07
CN103269692B (zh) 2018-02-23
MX2013001342A (es) 2013-03-22
MX353105B (es) 2017-12-19
EA030145B1 (ru) 2018-06-29
JP6441267B2 (ja) 2018-12-19
CA2807135A1 (en) 2012-02-09
KR20180008918A (ko) 2018-01-24
JP2017002074A (ja) 2017-01-05
TW201208667A (en) 2012-03-01
NZ607485A (en) 2015-04-24
BR112013002511A2 (pt) 2017-06-27
AU2011285928A1 (en) 2013-03-07
AU2011285928B9 (en) 2018-08-02
CN103269692A (zh) 2013-08-28
JP2013535486A (ja) 2013-09-12
KR20130135239A (ko) 2013-12-10
SG187689A1 (en) 2013-03-28
AP2013006742A0 (en) 2013-02-28
US20120035118A1 (en) 2012-02-09
SG10201506076TA (en) 2015-09-29
CO6680685A2 (es) 2013-05-31

Similar Documents

Publication Publication Date Title
AR084122A1 (es) COMBINACIONES FARMACEUTICAS, DE UN AGONISTA DE RECEPTOR b-3 ADRENERGICO Y UN ANTAGONISTA DE RECEPTOR MUSCARINICO
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
SV2010003642A (es) Compuestos
MX2009006304A (es) Nuevos compuestos de oxadiazol.
MX2013006304A (es) Analogos de glucagon que exhiben actividad del receptor gip.
EA201290266A1 (ru) Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CL2014001280A1 (es) Compuestos derivados de 4-fenil -piridinas sustituidas, moduladores del receptor de nk1; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de la emesis, disfuncion vesical, depresion o ansiedad
MY160665A (en) Spiropiperidine compounds as orl-1 receptor antagonists
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
CL2013000378A1 (es) Combinacion farmaceutica que comprende un farmaco antipsicotico atipico, tal como risperidona y olanzapina, entre otros, y un compuesto derivado de piperazina-fenil-metanona, antagonista del receptor de glyt1; método de tratamiento; y su uso para el tratamiento de sintomas positivos y negativos de la esquizofrenia.
ECSP12012213A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos ? 2 y como antagonistas muscarinicos m3
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
GB0812642D0 (en) Compounds
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
BRPI0910780A2 (pt) uso de antagonistas de opióides para o tratamento da retenção urinária
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
EA201270790A1 (ru) Соединение пиперидинила в качестве модулятора активности хемокинового рецептора

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure